BHLHB2 Overexpression Is a Positive Prognostic Factor Indicating Gemcitabine Responsiveness in Pancreatic Cancer

被引：0
|
作者：
Reiser-Erkan, C. [1 ]
Wang, W. [1 ]
Erkan, M. [1 ]
Michalski, C. W. [1 ]
Friess, Helmut [1 ]
Kleeff, J. [1 ]
机构：
[1] Tech Univ Munich, Dept Surg, Munich, Germany
来源：
PANCREAS | 2010年 / 39卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1343 / 1343
页数：1
相关论文
共 50 条
  • [1] Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma
    Wang, Weibin
    Reiser-Erkan, Carolin
    Michalski, Christoph W.
    Raggi, Matthias C.
    Quan, Liao
    Yupei, Zhao
    Friess, Helmut
    Erkan, Mert
    Kleeff, Joerg
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 401 (03) : 422 - 428
  • [2] Gemcitabine Treatment in Pancreatic Cancer - Prognostic Factors and Outcome
    Andersson, B.
    Aho, Ursula
    Pendse, Marie-Louise
    Nilsson, J.
    Tingstedt, B.
    Andersson, R.
    ANNALS OF GASTROENTEROLOGY, 2007, 20 (02): : 130 - 137
  • [3] Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients
    Omote, Shizuma
    Takata, Katsuyoshi
    Tanaka, Takehiro
    Miyata-Takata, Tomoko
    Ayada, Yoshiyuki
    Noujima-Harada, Mai
    Omote, Rika
    Tabata, Tetsuya
    Sato, Yasuharu
    Toyokawa, Tatsuya
    Kato, Hironari
    Yagi, Takahito
    Okada, Hiroyuki
    Yoshino, Tadashi
    MEDICAL MOLECULAR MORPHOLOGY, 2018, 51 (04) : 237 - 243
  • [4] Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients
    Shizuma Omote
    Katsuyoshi Takata
    Takehiro Tanaka
    Tomoko Miyata-Takata
    Yoshiyuki Ayada
    Mai Noujima-Harada
    Rika Omote
    Tetsuya Tabata
    Yasuharu Sato
    Tatsuya Toyokawa
    Hironari Kato
    Takahito Yagi
    Hiroyuki Okada
    Tadashi Yoshino
    Medical Molecular Morphology, 2018, 51 : 237 - 243
  • [5] Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine
    Aki Otake
    Daiki Tsuji
    Keisei Taku
    Yohei Kawasaki
    Mari Yokoi
    Harumi Nakamori
    Marika Osada
    Megumi Matsumoto
    Kazuyuki Inoue
    Keita Hirai
    Kunihiko Itoh
    European Journal of Clinical Pharmacology, 2017, 73 : 1033 - 1039
  • [6] Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine
    Otake, Aki
    Tsuji, Daiki
    Taku, Keisei
    Kawasaki, Yohei
    Yokoi, Mari
    Nakamori, Harumi
    Osada, Marika
    Matsumoto, Megumi
    Inoue, Kazuyuki
    Hirai, Keita
    Itoh, Kunihiko
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (08) : 1033 - 1039
  • [7] Prognostic Impact of DHRS9 Overexpression Pancreatic Cancer in Pancreatic Cancer
    Li, Huang-bao
    Zhou, Jun
    Zhao, Fengqing
    Yu, Jiayin
    Xu, Longsheng
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 5997 - 6006
  • [8] Gene structure and chromosomal location of a human bHLH transcriptional factor DEC1•Stra13•SHARP-2/BHLHB2
    Teramoto, M
    Nakamasu, K
    Noshiro, M
    Matsuda, Y
    Gotoh, O
    Shen, M
    Tsutsumi, S
    Kawamoto, T
    Iwamoto, Y
    Kato, Y
    JOURNAL OF BIOCHEMISTRY, 2001, 129 (03): : 391 - 396
  • [9] Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu, Naotake
    Okamoto, Aikou
    Kamata, Yuko
    Misawa, Takeyuki
    Uwagawa, Tadashi
    Gocho, Takeshi
    Yanaga, Katsuhiko
    Manome, Yoshinobu
    ONCOLOGY REPORTS, 2010, 23 (02) : 471 - 475
  • [10] Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
    Jonckheere, N.
    Fauquette, V.
    Stechly, L.
    Saint-Laurent, N.
    Aubert, S.
    Susini, C.
    Huet, G.
    Porchet, N.
    Van Seuningen, I.
    Pigny, P.
    BRITISH JOURNAL OF CANCER, 2009, 101 (04) : 637 - 644
12345